FDA authorizes Byetta as adjunct therapy to insulin Lantus

10/19/2011 | Wall Street Journal, The

The FDA is allowing the use of Eli Lilly and Co. and Amylin Pharmaceuticals' type 2 diabetes medicine Byetta as an add-on to Sanofi's Lantus, or insulin glargine. Byetta can be taken with or without metformin and thiazolidinedione, and in addition to diet and exercise.

View Full Article in:

Wall Street Journal, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health